|
Definition (NCI)
|
A ring-substituted amphetamine derivative, structurally related to the hallucinogen mescaline, with entactogenic, neurotoxic, and motor-stimulatory activities. 3,4-methylenedioxymethamphetamine (MDMA) produces an acute, rapid enhancement in both the release of serotonin from and the inhibition of serotonin reuptake by serotonergic nerve endings in the brain. Once within the cell, MDMA depletes stores of tryptophan hydroxylase (TPH) via acute oxidative inactivation; in turn, depleted stores of TPH leave cell terminals open to damage from oxidative stress, possibly a source of MDMA neurotoxicity. This agent also induces norepinephrine, dopamine, and acetylcholine release and can act directly on a number of receptors, including alpha 2-adrenergic and 5-hydroxytryptamine (5-HT) 2A receptors. MDMA may suppress the dyskinesia associated with long-term use of L-dopamine (L-DOPA) without affecting the efficacy of L-DOPA treatment.
|
|
Definition (MSH)
|
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
|
|
Definition (CSP)
|
synthetic adrenergic agonist resembling both amphetamine (a stimulant) and mescaline (a hallucinogen); "designer drug" once touted as potentially psychotherapeutic, but now a controlled substance considered a drug of abuse.
|
|
Definition (PDQ)
|
A ring-substituted amphetamine derivative, structurally related to the hallucinogen mescaline, with entactogenic (openess- and empathy-generating), neurotoxic, and motor-stimulatory activities. Although the mechanism by which it causes its unusual entactogenic effects is largely unknown, 3,4-methylenedioxymethamphetamine (MDMA) produces an acute, rapid enhancement in both the release of serotonin from and the inhibition of serotonin reuptake by serotonergic nerve endings in the brain. Once within the cell, MDMA depletes stores of tryptophan hydroxylase (TPH) via acute oxidative inactivation; in turn, depleted stores of TPH leave cell terminals open to damage from oxidative stress, possibly a source of MDMA neurotoxicity. This agent also induces norepinephrine, dopamine, and acetylcholine release and can act directly on a number of receptors, including alpha 2-adrenergic and 5-hydroxytryptamine (5-HT) 2A receptors. MDMA may suppress the dyskinesia associated with long-term use of L-dopamine (L-DOPA) without affecting the efficacy of L-DOPA treatment, perhaps via indirect stimulation of 5-HT 1A receptors. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475676&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475676&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61081" NCI Thesaurus)
|
| Concepts |
Pharmacologic Substance
(T121)
, Hazardous or Poisonous Substance
(T131)
, Organic Chemical
(T109)
|
| MSH |
D018817
|
| SnomedCT |
288459003, 229010005, 79838002, 386996008, 115539008 |
| LNC |
LP18612-9, MTHU004797 |
| English |
MDMA, Ecstasy (Drug), Methylenedioxymethamphetamine, N Methyl 3,4 methylenedioxyamphetamine, N-Methyl-3,4-methylenedioxyamphetamine, 1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-, 3,4 methylenedioxymethamphetamine, MMDA, 3-Methoxy-4,5- methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, METHYLMETHYLENEDIOXYAMPHETAMINE N 03 04, Ecstasy - drug, E - Ecstasy, Ecstasy, 3,4-Methylenedioxymethamphetamine, MDMA - Methylenedioxymethamphe, ecstasy (drug), Ecstasy - agent, N-Methyl-3,4-methylenedioxyamphetamine [Chemical/Ingredient], mdma, ecstasy, ecstasy drug, mdm, methylene dioxymethamphetamine, methylenedioxymethamphetamine, XTC, n-Methyl-3, 4-methylenedioxyamphetamine (substance), n-Methyl-3, 4-methylenedioxyamphetamine, Ecstasy - agent (substance), Methylene-dioxymethamphetamine (substance), MDM, MDMA - Methylenedioxymethamphetamine, Methylene-dioxymethamphetamine (product), Methylene-dioxymethamphetamine, Methylenedioxymethamphetamine (substance), Ecstasy - drug (substance), Methylenedioxymethamfetamine |
| Swedish |
N-metyl-3,4-metylendioxyamfetamin
|
| Spanish |
3-metoxi-4,5-metilendioxianfetamina, MMDA, Methylenedioxymethamphetamine, MDMA - Methylenedioxymethamphetamine, Methylenedioxymethamphetamine (substance), metilen-dioximetanfetamina (sustancia), éxtasis - agente (sustancia), n-metil-3,4-metilenedioxianfetamina, n-metil-3,4-metilenedioxianfetamina (sustancia), metilen-dioximetanfetamina, éxtasis - agente, metilendioximetanfetamina (producto), metilendioximetanfetamina, metilendioximetanfetamina (sustancia), MDMA, Metilenodioximetanfetamina, N-Metil-3,4-metilenodioxianfetamina |
| Czech |
extáze, MDMA, N-methyl-3,4-methylendioxyamfetamin |
| Finnish |
N-metyyli-3,4-metyleenidioksiamfetamiini
|
| Russian |
N-METIL-3,4-METILENDIOKSIAMFETAMIN, METILENDIOKSIAMFETAMIN, METILENDIOKSIMETAMFETAMIN, MDMA, N-МЕТИЛ-3,4-МЕТИЛЕНДИОКСИАМФЕТАМИН, МЕТИЛЕНДИОКСИАМФЕТАМИН, МЕТИЛЕНДИОКСИМЕТАМФЕТАМИН |
| Japanese |
N-メチル-3,4-メチレンジオキシアンフェタミン, メチレンジオキシメタンフェタミン |
| German |
METHYLMETHYLENDIOXYAMPHETAMIN N 03 04, MDMA, Methylendioxymethamphetamin, N-Methyl-3,4-Methylendioxyamphetamin, Ecstasy |
| French |
N-Méthyl-3,4-méthylènedioxy-amphétamine, N-Méthyl-3,4-méthylènedioxyamphétamine, Ecstasy, MDMA, Méthylènedioxymethamphétamine |
| Polish |
MEDMA, Metylenedioksymetamfetamina, N-metylo-3,4-metylenodioksyamfetamina |
| Portuguese |
N-Metil-3,4-Metilenodioxianfetamina, MDMA, Metilenodioximetanfetamina |
| Italian |
n-Metil-3,4-metilenediossiamfetamina
|
